ReviewEndocrine connections2021
Endocrine toxicity of cancer immunotherapy: clinical challenges.
Review in Endocrine connections, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- The Rise of Oncoendocrinology: How Modern Cancer Therapies Are Reshaping Endocrine Practice.Medical sciences (Basel, Switzerland) · 2026Review
- Adverse drug reaction assessment of pembrolizumab and nivolumab in esophageal cancer treatment based on the US FAERS database.Frontiers in immunology · 2026Article
- Endocrine immune-related adverse events in advanced lung cancer patients receiving immune checkpoint inhibitors: incidence, predictors and outcomes.Translational lung cancer research · 2025Article
- Review
- Development and validation of a nomogram for predicting immune-related thyroid dysfunction during immunotherapy in non-small cell lung cancer: a prospective cohort study in China.Frontiers in immunology · 2025Article
- Thyroid disorders induced by immune checkpoint inhibitors.Endocrine · 2024Review
- Unveiling the Etiopathogenic Spectrum of Hypophysitis: A Narrative Review.Journal of personalized medicine · 2023Review
- Challenges and Limitations of Endocrine Toxicity Evaluation in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy-Retrospective Study from a Tertiary-Level Hospital in Romania.Diagnostics (Basel, Switzerland) · 2023Article
- Pituitary hypoadrenocorticism and hypothyroidism after immunochemotherapy followed by salvage surgery for lung cancer: a case report.General thoracic and cardiovascular surgery cases · 2023Article
- Grading Central Diabetes Insipidus Induced by Immune Checkpoint Inhibitors: A Challenging Task.Frontiers in endocrinology · 2022Review
- Molecular and Genetic Immune Biomarkers of Primary and Immune-Therapy Induced Hypophysitis: From Laboratories to the Clinical Practice.Journal of personalized medicine · 2021Review
- Autoimmune Complications in Hematologic Neoplasms.Cancers · 2021Review
- UPDATES IN ENDOCRINE IMMUNE-RELATED ADVERSE EVENTS IN ONCOLOGY IMMUNOTHERAPY.Acta endocrinologica (Bucharest, Romania : 2005)Article
- Prevalence of Various Endocrinopathies Resulting from Use of Immune Checkpoint Inhibitors - A Prospective Study from a Tertiary Care Centre in India.Indian journal of endocrinology and metabolismArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors are now widely used in the treatment of multiple cancers. The major toxicities of these treatments are termed immune-related adverse events and endocrine dysfunction is common. Thyroid disease, hypopituitarism and a form of diabetes resembling type 1 diabetes are now all well described, with different patterns emerging with different checkpoint inhibitors. We review the presentation and management of the common endocrine immune-related adverse events, and discuss a number of recent advances in the understanding of these important, potentially life threatening toxicities. We also discuss some remaining dilemmas in management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.